Palliative treatment of painful bone metastases from non-Hodgkin lymphoma with disodium pamidronate

Journal of Experimental and Clinical Cancer Research

Volumn 21, Issue 3, 2002, Pages 429-432

  Pistevou Gombaki, K ^a   Eleftheriadis, N ^a   Sofroniadis, I ^a   Makris, P ^a   Kouloulias, V ^a  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

Disodium pamidronate; Non Hodgkin lymphoma; Osseous metastases; Palliative treatment

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; COBALT 60; PAMIDRONIC ACID;

AGED; ANALGESIA; ARTICLE; BONE METASTASIS; BONE PAIN; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CASE REPORT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HEAD AND NECK CANCER; HUMAN; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SIDE EFFECT; TONSIL CANCER; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; COMBINED MODALITY THERAPY; DIPHOSPHONATES; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; PAIN; PAIN MEASUREMENT; PALLIATIVE CARE;

EID: 0036740094     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Nielsen O.S., Munro A.J., Tannock I.F.: Bone metastases: pathophysiology and management policy. J. Clin. Oncol. 9:509-524, 1991.
2. Bertolini D.R., Nedwin G.E., Bringman T.S., Smith D.D. and Mundy G.R.: Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factors. Nature 319:516-518, 1986.
3. Hillner B.: The role of biphosphonates in metastatic breast cancer. Seminars in Radiation Oncology 10:250-253, 2000.
4. Carey P.O., Lippert M.C.: Treatment of painful prostatic bone metastases with oral etidronate disodium. Urology 32:403-407, 1988.
5. Diener K.M.: Bisphosphonates for controlling pain from metastatic bone disease Am. J. Health. Syst. Pharm. 53:1917-1927, 1996.
6. Cascinu S., Graziano F., Alessandroni P., Ligi M., Del Ferro E., Rossi D., et al.: Different doses of pamidronate in patients with painful osteolytic bone metastases. Support. Care Cancer 6:139-143, 1998.
7. Vinholes J.J., Purohit O.P., Abbey M.E., Eastell R., Coleman R.E.: Relationships between biochemical and symptomatic response in a double- blind randomized trial of pamidronate for metastatic bone disease. Ann. Oncol. 8:1243-1250, 1997.
8. Vinholes J., Guo C.Y., Purohit O.P., Eastell R., Coleman R.E.: Metabolic effects of pamidronate in patients with metastatic bone disease. Br. J. Cancer 73:1089-1095, 1996.
9. Flanagan A.M., Chambers T.J.: Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone. Calcif. Tissue. Int. 49:407-415, 1991.
10. Body J-J.: Bisphosphonates. Eur. J. Cancer 34:263-269, 1998.
11. Hillner B.E., Ingle J.N., Berenson J.R., Janjan N.A., Albain, K.S., Lipton A., et al.: American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J. Clin. Oncol. 18:1378-1391, 2000.
12. Rosenthal H., Kolb R., Gratz K.F., Reiter A., Galanski M.: Bone manifestations in non-Hodgkin's lymphoma in childhood and adolescence. Radiologie 40:737-744, 2000.
13. Baar J., Burkes R.L., Gospodarowicz M.: Primary non-Hodgkin's lymphoma of bone. Sem. Oncol. 26:270-275, 1999.
14. Coppes M.J., Patte C., Couanet D., Caillaud J.M., Salloum E., Brugieres L., et al: Childhood malignant lymphoma of bone. Med. Pediatr. Oncol. 19:22-27, 1991.
15. Janoskuti L., Szilvasi I., Papp G., Rona E., Benedek S., Fekete S.: Bone scanning and radiography in the evaluation of patients with malignant lymphoma. ROFO. Fortschr. Geb. Rontgenstr. Nuklearmed. 149:427-428, 1988.
16. Orzel J.A., Sawaf N.W., Richardson M.L.: Lymphoma of the skeleton: scintigraphic evaluation. Am. J. Roentgenol. 150:1095-1099, 1988.
17. Ngan H., Preston B.J.: Non-Hodgkin's lymphoma presenting with osseous lesions. Clin. Radiol. 26:351-356, 1975.
18. Theriault R.L., Lipton A., Hortobagyi G.N., Leff R., Gluck S., Stewart J.F. et al.: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial-Protocol 18 Aredia Breast Cancer Study Group. J. Clin. Oncol. 17:846-854, 1999.
19. Kouloulias V., Dardoufas C., Kouvaris J., Antypas C., Sandilos P., Matsopoulos G., et al.: New Approach in the Evaluation of the Use of Disodium Pamidronate in Conjunction with Radiotherapy in the Management of Bone Metastases Using Image Processing Techniques. Acta Oncol 2001 (in press).
20. Hortobagyi G., Theriault R., Lipton A., Porter L., Blayney D., Sinoff C., et al.: Long term prevention, of skeletal complications of metastatic breast cancer with Pamidronate. J. Clin. Oncol. 16:2038-2044, 1998.
21. Rosen H.N., Moses A.C., Garber J., Ross D.S., Lee S.L., Greenspan S.L.: Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates. Calcif. Tissue. Int. 63:363-368, 1998.